Sort
82,697 grants matching “vaccine development”
Capsule conjugate vaccines against Campylobacter jejuni
$1,322,611Patricia Guerry · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2010 · AI
Virus biology scientific research support component
$1,322,441Beatrice H Hahn · Duke University · UM1 · FY2013 · AI
Center of Research Translation on the Osteoimmunology of Bone Infection (CoRTOBI)
$1,322,427Edward M Schwarz · University Of Rochester · P50 · FY2024 · AR
Harnessing Human DC Subsets for Improved Muscosal Vaccines
$1,322,064Jacques F Banchereau · Baylor Research Institute · U19 · FY2010 · AI
VACCINE AND TREATMENT EVALUATION UNITS (VTEU)
$1,322,033Wendy Keitel · Baylor College Of Medicine · N01 · FY2018 · AI
Infant HIV Vaccination: B-cell Lineage Study
$1,322,017Ofer Levy · Boston Children'S Hospital · N01 · FY2019 · AI
iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium
$1,321,621Eduardo Vilar Sanchez · University Of Tx Md Anderson Can Ctr · UG1 · FY2024 · CA
ECHO Renewal for the CANOE Study Cohort
$1,320,521Tina V Hartert · Vanderbilt University Medical Center · UG3 · FY2023 · OD
Malaria Transmission Blocking Vaccine Discovery
$1,320,426Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Epigenetic & Post-Translational Mechanisms of Macrophage Resistance to Mycobacterium tuberculosis During HIV Co-Infection
$1,319,833Thomas R Hawn · University Of Washington · R33 · FY2021 · AI
Aurum Clinical Trials Unit
$1,319,570Gavin John Churchyard · Aurum Institute Npc · UM1 · FY2023 · AI
UCSF HIV Clinical Trials Unit
$1,319,536Diane V Havlir · University Of California, San Francisco · U01 · FY2010 · AI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population
$1,319,208Beth Diane Kirkpatrick · University Of Vermont & St Agric College · U01 · FY2020 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS
$1,319,131Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2020 · AI
Molecular approaches to understand vector-host and vector-pathogen interactions
$1,318,361Jesus Valenzuela · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies
$1,318,233Cynthia E Dunbar · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL
Disseminated Tuberculosis in HIV Infection
$1,317,869C. Fordham Von Reyn · Dartmouth College · U01 · FY2006 · AI
Development of Nipah virus mRNA vaccine
$1,317,404Rosemarie Mason · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
DEVELOPMENT OF CANDIDA-STAPHYLOCOCCUS VACCINE
$1,316,999Duke University · · FY2008 · Department of Defense
Replication Dynamics in Patients on Suppressive Antiretroviral Therapy
$1,316,983Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
ESTABLISHMENT OF SPECIFIC PATHOGEN FREE RHESUS AND PIGTA
$1,316,833Oregon Health And Science University · U24 · FY2003 · RR
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development
$1,316,712Thomas William Geisbert · Boston University Medical Campus · U01 · FY2009 · AI
Heat Shock Protein and Thermal Therapy of Cancer
$1,316,642Roswell Park Cancer Institute Corp · P01 · FY2003 · CA
Immunotherapy to prevent drug-resistant tuberculosis
$1,315,804Rhea N Coler · Access To Advanced Health Institute · R01 · FY2016 · AI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit
$1,315,740Pablo Tebas · University Of Pennsylvania · UM1 · FY2015 · AI